Abstract
Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxygen species by chelating redox-active iron and thereby may reduce ischemia-reperfusion injury and myocardial infarct (MI) size. We investigated whether DFO administered before reperfusion by primary percutaneous coronary intervention (PPCI) would ameliorate oxidative stress and MI size.
| Original language | English |
|---|---|
| Pages (from-to) | 270 - 278 |
| Number of pages | 9 |
| Journal | Circulation: Cardiovascular Interventions |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2012 |